R&D

China overtakes US in contributions to nature and science journals
China overtakes US in contributions to nature and science journals
The Guardian, UK
China
R&D
academic research
Flag link:
Serial biotech founder Tim Springer on investing in startups and democratizing antibody research
Serial biotech founder Tim Springer on investing in startups and democratizing antibody research
BioPharma Dive
Tim Springer
Harvard
biotech
R&D
Flag link:
10 Trends and Statistics for Clinical Trials in 2023
10 Trends and Statistics for Clinical Trials in 2023
Xtalks
clinical trials
R&D
CROs
Flag link:
UCB partners with Ariceum for treatment of immune-related diseases and cancer
UCB partners with Ariceum for treatment of immune-related diseases and cancer
Biopharma Reporter
UCB Pharma
Ariceum
R&D
radiopharmaceuticals
solid tumors
Flag link:
Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup
Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup
Fierce Biotech
Takeda
R&D
gene therapy
earnings
Crohn’s disease
Flag link:
BMS Cuts Jobs in New Jersey, Cites ‘Constantly Evolving’ Business Model
BMS Cuts Jobs in New Jersey, Cites ‘Constantly Evolving’ Business Model
BioSpace
Bristol Myers Squibb
layoffs
R&D
New Jersey
Flag link:
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
BioSpace
Biogen
Novartis
Sanofi
earnings
R&D
Flag link:
Roche opens new institute to advance research in human model systems
Roche opens new institute to advance research in human model systems
Pharmaceutical Technology
Roche
R&D
organoids
Switzerland
Flag link:
Industry Seeks to Stimulate Innovation Through Grant Programs
Industry Seeks to Stimulate Innovation Through Grant Programs
BioSpace
grants
R&D
Thermo Fisher Scientific
Merck KGaA
Qiagen
Flag link:
Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?
Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?
BioSpace
Biogen
Qalsody
tofersen
ALS
drug development
R&D
Flag link:
Boehringer Ingelheim opens new biotechnology R&D center in Germany
Boehringer Ingelheim opens new biotechnology R&D center in Germany
Pharmaceutical Business Review
Boehringer Ingelheim
Germany
R&D
Flag link:
Mount Sinai launches regenerative medicine outpost to translate research into medicines
Mount Sinai launches regenerative medicine outpost to translate research into medicines
Fierce Biotech
Mount Sinai
regenerative medicine
R&D
Flag link:
Big Pharma’s R&D spending flatlined in 2022: What it means for the industry
Big Pharma’s R&D spending flatlined in 2022: What it means for the industry
Medical Marketing and Media
R&D
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Fierce Biotech
Boehringer Ingelheim
RetinAI
artificial intelligence
geographic atrophy
R&D
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:
Regeneron expects $56M IPR&D charge tied to cell therapy pact
Regeneron expects $56M IPR&D charge tied to cell therapy pact
Fierce Biotech
Regeneron
earnings
R&D
Sonoma Biotherapeutics
Flag link:
Layoffs loom as Takeda trims early-stage efforts in AAV gene therapy, rare hematology
Layoffs loom as Takeda trims early-stage efforts in AAV gene therapy, rare hematology
Fierce Biotech
Takeda
R&D
gene therapy
hematology
Flag link:
AbbVie knocks down earnings forecast due to IPR&D charge
AbbVie knocks down earnings forecast due to IPR&D charge
Fierce Biotech
AbbVie
R&D
Flag link:

Pages